| Dr Gina Direnzo-coffey, MD | |
|
14080 Hospital Rd, Boys Town, NE 68010-7513 | |
| (402) 778-6900 | |
| (402) 778-6917 |
| Full Name | Dr Gina Direnzo-coffey |
|---|---|
| Gender | Female |
| Speciality | Pediatrics |
| Location | 14080 Hospital Rd, Boys Town, Nebraska |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194880740 | NPI | - | NPPES |
| 1200589 | Medicaid | NE | |
| 35173 | Other | NE | MIDLANDS CHOICE |
| 0538587 | Medicaid | IA | |
| 1538587 | Medicaid | IA | |
| 1200598 | Medicaid | NE | |
| 1200599 | Medicaid | NE | |
| 1200600 | Medicaid | NE | |
| 1201446 | Medicaid | NE | |
| 1201455 | Medicaid | NE | |
| 03484 | Other | NE | BCBS |
| 1200597 | Medicaid | NE | |
| 2538587 | Medicaid | IA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 21462 (Nebraska) | Primary |
| 2080P0206X | Pediatrics - Pediatric Gastroenterology | 21462 (Nebraska) | Secondary |
| Entity Name | Father Flanagans Boys Home |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295821825 PECOS PAC ID: 9638165400 Enrollment ID: O20040426000622 |
News Archive
Ambassador-at-Large for Global Women's Issues Melanne Verveer and U.S. Global AIDS Coordinator Ambassador Eric Goosby on Monday "announced a joint initiative to provide $4.65 million in small grants to grassroots organizations to address gender-based violence (GBV) issues" through HIV/AIDS programs, according to a State Department press release.
Scientists at the MedUni Vienna, in collaboration with a working group led by Nancy Hynes at the University of Basel, have discovered a new approach in the treatment of breast cancer: an international team involving the Clinical Institute of Pathology at the MedUni Vienna has been able to demonstrate the activation of a receptor, the Ret protein (Rearranged during transfection), on the surface of breast cancer cells. Increased levels of this protein are associated with a lower likelihood of survival for breast cancer patients.
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.
House Democratic leaders on Thursday unveiled an aggressive plan to lower drug prices through negotiations between federal health officials and the makers of some of the most expensive drugs.
35% of small firms believe that the recent introduction of the fit note will have a 'very negative' impact on their business, a new survey from comparison site Constructaquote.com http://www.constructaquote.com/ has revealed.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gina Direnzo-coffey, MD 555 N 30th St, Omaha, NE 68131-2136 Ph: (402) 280-8100 | Dr Gina Direnzo-coffey, MD 14080 Hospital Rd, Boys Town, NE 68010-7513 Ph: (402) 778-6900 |
News Archive
Ambassador-at-Large for Global Women's Issues Melanne Verveer and U.S. Global AIDS Coordinator Ambassador Eric Goosby on Monday "announced a joint initiative to provide $4.65 million in small grants to grassroots organizations to address gender-based violence (GBV) issues" through HIV/AIDS programs, according to a State Department press release.
Scientists at the MedUni Vienna, in collaboration with a working group led by Nancy Hynes at the University of Basel, have discovered a new approach in the treatment of breast cancer: an international team involving the Clinical Institute of Pathology at the MedUni Vienna has been able to demonstrate the activation of a receptor, the Ret protein (Rearranged during transfection), on the surface of breast cancer cells. Increased levels of this protein are associated with a lower likelihood of survival for breast cancer patients.
Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that it presented data at the NCDEU 50th Anniversary Meeting showing that its novel mechanism compound GLYX-13 appeared safe in a Phase I trial. GLYX-13 is a glycine site functional partial agonist selective modulator of the NMDA receptor that is being developed initially for use in depression as adjunctive therapy.
House Democratic leaders on Thursday unveiled an aggressive plan to lower drug prices through negotiations between federal health officials and the makers of some of the most expensive drugs.
35% of small firms believe that the recent introduction of the fit note will have a 'very negative' impact on their business, a new survey from comparison site Constructaquote.com http://www.constructaquote.com/ has revealed.
› Verified 9 days ago
Dr. Kenton R. Amstutz, D.O. Pediatrics Medicare: Medicare Enrolled Practice Location: 14080 Hospital Rd, Boys Town, NE 68010 Phone: 402-778-6900 Fax: 402-778-6917 | |
Dr. Michael G Dawson, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 14080 Hospital Rd, Boys Town, NE 68010 Phone: 402-778-6900 Fax: 402-778-6917 | |
Daniel Reiff, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 14080 Boys Town Hospital Rd, Boys Town, NE 68010 Phone: 531-355-6863 Fax: 531-355-7449 | |
Danielle Empson, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 14080 Boys Town Hospital Rd, Boys Town, NE 68010 Phone: 402-778-6900 | |
Andrea L Zimmer, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 14080 Boys Town Hospital Rd, Boys Town, NE 68010 Phone: 402-778-6900 | |
Dr. Monica Maria Kelly, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 14080 Boys Town Hospital Rd, Boys Town, NE 68010 Phone: 531-355-6900 |